Oxymetholone
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Oxymetholone: From Unspecified Original Indication to Seborrhoeic Dermatitis
One-Sentence Summary
Oxymetholone is an anabolic-androgenic steroid; no original indication data is currently on record for this evidence pack. The TxGNN model predicts a possible association with Seborrhoeic Dermatitis (score 99.05%), but this is supported by no clinical trials and no published literature, and the underlying pharmacology points in the opposite direction to a therapeutic benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in current data (no original_indications on file) |
| Predicted New Indication | Seborrhoeic Dermatitis |
| TxGNN Prediction Score | 99.05% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable? (Caution Advised)
Detailed mechanism of action data is not currently available in this evidence pack. Based on known pharmacological class information, Oxymetholone is an anabolic-androgenic steroid (AAS).
Androgens are well established to stimulate sebaceous gland proliferation and increase sebum production — this is precisely the mechanism believed to drive seborrhoeic dermatitis and acne, not treat it. Clinically, acne and increased sebum production are recognised adverse effects of androgen therapy. This places the predicted indication in direct mechanistic opposition to a plausible therapeutic effect.
The high TxGNN score (99.05%) most likely reflects strong graph connectivity between “androgen” and “sebaceous gland/skin” nodes in the knowledge graph — a reflection of a well-documented adverse pharmacological relationship rather than a therapeutic one. This prediction should be treated as a candidate false positive pending mechanistic review, and is not, on current evidence, a credible repurposing lead.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Oxymetholone does not currently hold a marketing authorisation and has a UK market status of Not marketed. No licence records are available to summarise.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications and drug interaction data for Oxymetholone are not currently available in this evidence pack (flagged as a blocking data gap — see Conclusion).
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence level is L5 (model prediction only) — no clinical trials or literature support this indication.
- The proposed mechanism runs counter to the biological direction expected for treating seborrhoeic dermatitis, raising strong suspicion of a false positive driven by knowledge-graph node connectivity rather than genuine therapeutic signal.
- A blocking data gap exists on TFDA/SmPC-equivalent warnings and contraindications, meaning this candidate cannot yet enter a formal safety pre-assessment (S1).
To proceed, the following is needed:
- Full prescribing information (warnings, contraindications) to close the blocking data gap before any safety pre-assessment can begin.
- Confirmed mechanism of action data from DrugBank or equivalent source.
- An independent mechanistic review to assess whether the TxGNN score reflects a genuine therapeutic hypothesis or a graph-connectivity artefact, before any further evidence collection is commissioned for this indication.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.